Moleculin Reports Additional Preliminary Interim Data From AML Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Moleculin Biotech, Inc. (MBRX) reported additional preliminary interim data from its AML clinical trial, showing promising results in subjects with poor prognosis cytogenetics and/or mutations. The trial demonstrated a median durability of response of 6 months and increasing, with significant survival rates and no cardiotoxicity. The data was presented at the European Hematology Association 2024 Hybrid Congress.
June 14, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moleculin Biotech, Inc. (MBRX) reported promising interim data from its AML clinical trial, showing significant survival rates and no cardiotoxicity. This positive data could boost investor confidence and potentially drive the stock price up in the short term.
The positive interim data from the AML clinical trial, including significant survival rates and no cardiotoxicity, is likely to boost investor confidence. This could lead to a short-term increase in MBRX's stock price as the market reacts to the promising results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100